Date: 2012-04-02
Type of information: R&D agreement
Compound: antibody-drug conjugates (ADCs)
Company: PolyTherics (UK) Spirogen (UK)
Therapeutic area: Cancer Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: PolyTherics has formed a research collaboration with Spirogen to develop antibody-drug conjugates (ADCs) that combine PolyTherics’ proprietary site-specific conjugation chemistry with Spirogen’s highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer. Under the collaboration, the two companies will produce the ADCs using PolyTherics’ proprietary TheraPEG™ linker technology to site-specifically conjugate Spirogen’s pyrrolobenzodiazepines (“PBDs”) cytotoxic agents – known as warheads - to antibodies and antibody fragments.
The companies will then test the potency of the resulting ADCs in preclinical models of cancer. PolyTherics and Spirogen will jointly seek partners to develop the most promising ADC candidates that arise from the collaboration.
Financial terms: Financial details were not disclosed.
Latest news:
